Trevi Therapeutics to present Phase 2b CORAL nalbuphine ER quality-of-life data in IPF cough at ERS 2026
TRVI•ERS 2026 presentations on nalbuphine ER
Trevi Therapeutics set two ERS Congress 2026 presentations for September 7 in Barcelona on nalbuphine ER for chronic cough.
Results have not been presented yet; the company will disclose quality-of-life findings from Phase 2b CORAL in IPF-related chronic cough.
A second presentation will cover quality-of-life outcomes from the Phase 2a RIVER study in refractory chronic cough.
